The focus is on speed. Intelligent networking, automated processes and state-of-the-art robotics make central test steps 30 per cent faster. The centrepiece is a fully automated sample storage facility with 2.5 million biosamples at minus 80 degrees. Researchers can access it at the touch of a button. 630 kilometres of data cable and over 4,400 sensors control equipment, energy consumption and capacity utilisation in real time. In terms of content, Roche is targeting in-vitro diagnostics for neurology, cardiovascular diseases, infections and personalised medicine. Around 70 per cent of all medical decisions are based on diagnostics, but only a fraction of healthcare expenditure is spent in this area. The Group is also setting standards in terms of energy consumption. Thanks to wood-hybrid construction, photovoltaics and intelligent waste heat utilisation, consumption is 70 per cent lower than in previous laboratories. This is where research, efficiency and sustainability merge into an industrial answer to the medicine of tomorrow.
Press release by "Roche Deutschland Holding GmbH" dated 12 February 2026